Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Gilead Sciences Inc
GILD
Healthcare
Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products...
includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:GILD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(80)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 22, 2024 6:45pm
Why Gilead Sciences Stock Got Mashed on Monday
JUST IN: $GILD Why Gilead Sciences Stock Got Mashed on Monday2024-01-22 18:08:02 ET Pharmaceutical sector mainstay Gilead Sciences (NASDAQ: GILD) has had many good days on the stock exchange, but
...more
(80)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 22, 2024 6:30pm
Gilead Provides Update on Phase 3 EVOKE-01 Study
JUST IN: $GILD Gilead Provides Update on Phase 3 EVOKE-01 StudyGilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall
...more
Addition Of New Copper Claims at Topley Project
posted Apr 19, 2024 9:00am by
Geologica Resource Corp.
-
|
Geologica’s Topley Property is located in British Columbia, a global leader in the development of socially and environmentally responsible resources. Combined with a positive market sentiment for commodities like gold, silver, copper and molybdenum, Topley and Geologica are well-positioned to create significant value for shareholders ...read more
(80)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 14, 2023 3:00pm
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatme
NEWS: $GILD FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis-- Veklury is Now the First Approved Antiviral
...more
(0)
•••
Peng26
X
View Profile
View Bullboard History
Post by
Peng26
on Apr 13, 2023 5:19am
Kevin Harrington Speaks about FSD Pharma
FSD Pharma Inc is about to launch this breakthrough product!!
(1)
•••
Rebecca
X
View Profile
View Bullboard History
Post by
Rebecca
on Apr 13, 2023 3:13am
Kevin Harrington Discusses FSD Pharma
I believe this new product will aid society in reducing the
...more
(3)
•••
jonathanS
X
View Profile
View Bullboard History
Post by
jonathanS
on Aug 03, 2022 9:15am
roughly $80 billion biopharmaceutical company
The wide array of offerings helps fuel consistent payouts to shareholders. Current distributions are 73 cents per quarter, up 70% from 43 cents a share back at the beginning of 2016 and proof that
...more
(1)
•••
Rebecca
X
View Profile
View Bullboard History
Post by
Rebecca
on Jul 15, 2022 8:49pm
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent
(1)
•••
Rebecca
X
View Profile
View Bullboard History
Post by
Rebecca
on Jun 03, 2022 4:19am
FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance
(1)
•••
Rebecca
X
View Profile
View Bullboard History
Post by
Rebecca
on Jun 01, 2022 11:54pm
FSD Pharma Files Investigational New Drug Application “IND”
(1)
•••
Rebecca
X
View Profile
View Bullboard History
Post by
Rebecca
on May 10, 2022 11:55pm
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets
(1)
•••
Rebecca
X
View Profile
View Bullboard History
Post by
Rebecca
on May 03, 2022 9:45pm
Lucid-MS for Multiple Sclerosis Treatment
(1)
•••
Rebecca
X
View Profile
View Bullboard History
Post by
Rebecca
on Apr 26, 2022 1:18am
"Julia Levy Award" Recipient David Allan and Dr. John McGraw
(1)
•••
Rebecca
X
View Profile
View Bullboard History
Post by
Rebecca
on Apr 19, 2022 1:05am
FSD Pharma Inc: Lucid MS Video
FSD Pharma is delighted to announce pre-clinical findings
...more
(4)
•••
zeropointenergy
X
View Profile
View Bullboard History
Post by
zeropointenergy
on Oct 09, 2021 6:41am
IVERMICTIN KILLS COVID 19 !
NICE China Reports Zero New Locally Acquired Covid-19 Cases for Fourth Day in a Row
(4)
•••
zeropointenergy
X
View Profile
View Bullboard History
Post by
zeropointenergy
on Oct 06, 2021 7:39am
ONE DRUG PILL WIPES OUT COVID 19!
India's Ivermectin Blackout - Part V: The Secret Revealed ... Sep 27, 2021 · By September 12, 2021, Livemint reported that 34 districts were declared COVID-free
...more
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Positive PEA for Uranium-Vanadium Deposit After-tax NPV 8%: $227.7 million with IRR: 38.9%
Fokus Mining Welcomes Luc Gervais To Its Board Of Directors
The Increasing Investments by the Defense and Military Sectors is Driving the Demand for Helium